Abstract
Background and Aims: Despite progress in treating type 2 diabetes (T2D), patients have a high residual risk of cardiovascular complications. This may be due to incomplete management of T2D related dyslipidemia, characterized by high plasma TG, dense LDL (dLDL) and low HDL especially HDL2. Usually CVD risk is estimated based on LDL, HDL and TG, with LDL as primary target and statins as first treatment choice. This ‘’one-size-fits-all approach’’ is possibly insufficient. Identifying additional diagnostic and treatment targets might further reduce CVD risk in T2D. Our main objective is to optimize individual diagnosis and treatment of dyslipidemia in T2D using CVD risk classification based on in-depth lipoprotein profiling. Primary endpoint is difference in choice of lipid-lowering therapy when using conventional lipid panel versus in-depth lipoprotein profiling.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
